Pazopanib
- Generic Name
- Pazopanib
- Brand Names
- Votrient
- Drug Type
- Small Molecule
- Chemical Formula
- C21H23N7O2S
- CAS Number
- 444731-52-6
- Unique Ingredient Identifier
- 7RN5DR86CK
- Background
Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.
- Indication
Treatment of advanced renal cell cancer and advanced soft tissue sarcoma (in patients previously treated with chemotherapy)
- Associated Conditions
- Advanced Renal Cell Carcinoma, Advanced Soft Tissue Sarcoma, Advanced Thyroid cancer
Pazopanib for Metastatic Alveolar Soft Part Sarcoma
- First Posted Date
- 2014-04-15
- Last Posted Date
- 2017-11-06
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 6
- Registration Number
- NCT02113826
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Optimizing Pazopanib Exposure in RCC Patients
- Conditions
- Locally Advanced Renal Cell CarcinomaMetastatic Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2014-03-18
- Last Posted Date
- 2017-08-18
- Lead Sponsor
- Interessenverband zur Qualitätssicherung der Arbeit niedergelassener Uro-Onkologen in Deutschland e.
- Target Recruit Count
- 6
- Registration Number
- NCT02089802
- Locations
- 🇩🇪
Private Practice Kamann, Leipzig, Sachsen, Germany
🇩🇪Gesundheitszentrum Holzminden, Holzminden, Niedersachsen, Germany
🇩🇪Private Practice Geiges, Berlin, Germany
Trial of Pazopanib in Patients With Solitary Fibrous Tumor and Extraskeletal Myxoid Chondrosarcoma
- Conditions
- Solitary Fibrous TumorExtraskeletal Myxoid Chondrosarcoma
- Interventions
- First Posted Date
- 2014-02-19
- Last Posted Date
- 2023-03-27
- Lead Sponsor
- Grupo Espanol de Investigacion en Sarcomas
- Target Recruit Count
- 96
- Registration Number
- NCT02066285
- Locations
- 🇪🇸
Hospital Universitario Virgen del Rocío, Sevilla, Spain
🇪🇸Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
🇪🇸H. Son Espases, Palma De Mallorca, Islas Baleares, Spain
PAZOFOS: Phase Ib and Phase II Trial of Pazopanib +/- Fosbretabulin in Advanced Recurrent Ovarian Cancer
- Conditions
- Neoplasms, OvarianOvarian NeoplasmsOvarian Cancer
- Interventions
- First Posted Date
- 2014-02-05
- Last Posted Date
- 2021-05-17
- Lead Sponsor
- The Christie NHS Foundation Trust
- Target Recruit Count
- 21
- Registration Number
- NCT02055690
- Locations
- 🇬🇧
University Collage London Hospitals NHS Foundation Trust, London, United Kingdom
🇬🇧The Christie NHS Foundation Trust, Manchester, United Kingdom
🇬🇧Freeman Hospital (Newcastle-upon-Tyne Hospitals NHS Foundation Trust), Newcastle Upon Tyne, United Kingdom
Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment
- Conditions
- Malignant Solid Neoplasms
- Interventions
- Combination Product: Durvalumab + Tremelimumab
- First Posted Date
- 2014-01-07
- Last Posted Date
- 2024-02-13
- Lead Sponsor
- Centre Leon Berard
- Target Recruit Count
- 900
- Registration Number
- NCT02029001
- Locations
- 🇫🇷
Centre Hospitalier Lyon Sud, Lyon, France
🇫🇷Institut Bergonié, Bordeaux, France
🇫🇷Institut Claudius Regaud, Toulouse, France
Safety and Efficacy Study of Pazopanib and MK 3475 in Advanced Renal Cell Carcinoma (RCC; KEYNOTE-018)
- First Posted Date
- 2013-12-18
- Last Posted Date
- 2020-03-03
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 42
- Registration Number
- NCT02014636
- Locations
- 🇬🇧
Novartis Investigative Site, London, United Kingdom
A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors
- Conditions
- Prostate CancerPancreatic CarcinomaSolid TumorsBreast CancerMelanomaRenal Cell CarcinomaNon-small Cell Lung CarcinomaOvarian CancerColorectal Carcinoma
- Interventions
- Drug: Gemcitabine/carboplatinDrug: FOLFOX (Oxaliplatin/Leucovorin/5-Fluorouracil)Drug: gemcitabine/nab-paclitaxel
- First Posted Date
- 2013-12-12
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 353
- Registration Number
- NCT02009449
- Locations
- 🇺🇸
UCLA Medical Hematology & Oncology, Los Angeles, California, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Florida Cancer Specialists & Research Institute, Sarasota, Florida, United States
Individualizing Pazopanib Therapy by exploRing the Role of Early Metabolic responsE and Drug Exposure as a preDICTor for Treatment Outcome in Patients With STS
- First Posted Date
- 2013-11-27
- Last Posted Date
- 2017-12-19
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 22
- Registration Number
- NCT01995981
- Locations
- 🇳🇱
Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
🇬🇧Royal Marsden Hospital, London, United Kingdom
Combined Modality Treatment of Sarcomas of the Extremities
- First Posted Date
- 2013-11-15
- Last Posted Date
- 2015-10-09
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 12
- Registration Number
- NCT01985295
- Locations
- 🇳🇱
The Netherlands Cancer Institute, Amsterdam, Noord Holland, Netherlands
A Phase 1B Dose-escalation and Phase 2a Study of Carotuximab (TRC105) in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma
- First Posted Date
- 2013-11-03
- Last Posted Date
- 2020-05-20
- Lead Sponsor
- Tracon Pharmaceuticals Inc.
- Target Recruit Count
- 111
- Registration Number
- NCT01975519
- Locations
- 🇺🇸
Mount Sinai School of Medicine-Tisch Cancer Institute, New York, New York, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸Mayo Clinic Jacksonville, Jacksonville, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.